Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

Thomas P Miller, S. E. Jones, A. Chester

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.

Original languageEnglish (US)
Pages (from-to)1001-1003
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number8-9
StatePublished - 1980

Fingerprint

Vindesine
Lymphoma
Breast Neoplasms
Neoplasms
Non-Hodgkin's Lymphoma
Vinca
Ovarian Diseases
Therapeutics
Small Cell Lung Carcinoma
Neutropenia
Hodgkin Disease
Breast
Carcinoma
Injections
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors. / Miller, Thomas P; Jones, S. E.; Chester, A.

In: Cancer Treatment Reports, Vol. 64, No. 8-9, 1980, p. 1001-1003.

Research output: Contribution to journalArticle

@article{e09be874667c4e2a9ebc2e13bff0b2a0,
title = "Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors",
abstract = "A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18{\%}) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40{\%}). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10{\%} of the patients. high incidence of local tissue reactions at the injection site (27{\%}) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.",
author = "Miller, {Thomas P} and Jones, {S. E.} and A. Chester",
year = "1980",
language = "English (US)",
volume = "64",
pages = "1001--1003",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8-9",

}

TY - JOUR

T1 - Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

AU - Miller, Thomas P

AU - Jones, S. E.

AU - Chester, A.

PY - 1980

Y1 - 1980

N2 - A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.

AB - A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.

UR - http://www.scopus.com/inward/record.url?scp=0019254053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019254053&partnerID=8YFLogxK

M3 - Article

C2 - 7448818

AN - SCOPUS:0019254053

VL - 64

SP - 1001

EP - 1003

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8-9

ER -